C
뉴로핏
380550KOSDAQ45.0 / 100
Reference Date: 2026-10-23
Financial Score20.5 / 40
News Sentiment12.5 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 15.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Neurophet is a company specializing in medical imaging solutions for neurodegenerative diseases, particularly Alzheimer's, offering products like Neurophet AQUA AD, which assesses Amyloid-Related Imaging Abnormalities (ARIA) severity. The company holds international certifications such as CE, FDA 510K, and GMP, and provides Clinical Research Organization (CRO) services to support medical device development.
Number of Employees
139people
Average Salary
58.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
3.67Industry Average 1.200.0Point
3.1x industry avg (risky)
ROE
—Industry Average 8.003.5Point
Debt Ratio
2.55Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
2.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 5,850Won52-week high 36,70052-week low 5,700
1-month return0.0Point
1m -15.09% (strong drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0